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Introduction
Work done by this group nearly 7 years ago, evaluated a
cohort of patients who, for a variety of reasons, elected
to remain on a virologically failing ARV regimen. We
re-evaluated these patients to determine whether their
earlier years living with low level viremia impacted their
future treatment options. In the absence of a cure and
with the goal of maintaining HIV infection as a chronic,
yet manageable disease, it is important to understand
the consequences of persistent immune system
activation.
Materials and methods
Two community based HIV practices with nearly 1000
patients evaluated a subset of 25 patients on stable ARV
regimens for >24 months who refused treatment change
despite the presence of low level viremia. Patients were
counseled regarding the need for change. They acknowl-
edged a variety of reasons for their refusal including fear
of change and fear of the unknown; a comfort with their
current regimen; fear of “burning through options”,e t c .
Charts were reviewed for CD4 counts, HIV bDNA
levels, HIV related OIs or malignancies, as well as other
co-morbidities.
Results
As new HIV medications became available, patients
agreed to switch regimens. 19 of 25 patients were
started on regimens which resulted in virologic suppres-
sion below the level of quantification (BLQ). 1 patient
died of an MI and 1 died of a neuroendocrine tumor
and 4 patients were lost to follow-up. Given the potency
of the new regimens that were constructed, those
patients who switched were able to suppress without
significant difficulties.
Conclusions
With the new paradigm of test and treat despite CD4
level, we can expect to be treating many more patients
for longer periods of time. The issues of adherence and
“pill fatigue” are well known and contribute to patients’
potential inability to maintain fully suppressive regimens
for long and sustained periods of time. Our experience
of patients who refused to switch regimens despite low
levels of virus and yet, when ready, were able to fully
suppress with a regimen change, is encouraging.
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